Exploratory Biomarker Analysis of DESTINY-CRC01, a Phase II, Multicenter, Open-Label Study of Trastuzumab Deruxtecan (T-Dxd, DS-8201) in Patients (pts) with HER2-expressing Metastatic Colorectal Cancer (Mcrc)
ANNALS OF ONCOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要